CA
CSTL icon

Clearstead Advisors’s Castle Biosciences CSTL Stock Holding History

Clearstead Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15K Buy
+48
New +$1.07K ﹤0.01% 2655
2025
Q4 		– Sell
-12
Closed -$274 – 2859
2025
Q3 		$274 Buy
+12
New +$244 ﹤0.01% 2821
2022
Q2 		– Sell
-22
Closed -$1K – 1312
2022
Q1 		$1K Buy
+22
New +$909 ﹤0.01% 1272
2021
Q4 		– Sell
-116
Closed -$8K – 1306
2021
Q3 		$8K Buy
+116
New +$8.16K ﹤0.01% 971

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Clearstead Advisors's CSTL Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Castle Biosciences (CSTL) in Q2 2026: 48 shares worth $1.15K. The stake represents ﹤0.01% of the portfolio and ranks #2655 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in CSTL as recently as Q3 2025.

Clearstead Advisors first reported a position in CSTL in Q3 2021 and has held it in 4 quarters since. The position peaked at $8K in Q3 2021. 61 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Clearstead Advisors held 48 shares of Castle Biosciences worth $1.15K as of Q2 2026.
  • Castle Biosciences was a new Clearstead Advisors position in Q2 2026.
  • Castle Biosciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2655 holding.
  • Clearstead Advisors first reported a position in Castle Biosciences in Q3 2021 and has held it in 4 quarters since.
  • Clearstead Advisors's Castle Biosciences position peaked at $8K in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.